Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD

• Pharmacologic treatment recommendations are tailored to patients' needs based on symptoms and exacerbation history¹

• LAMA/LABA therapy now an essential cornerstone for COPD treatment across the spectrum of people with COPD in GOLD groups B-D¹

• Clearer guidance for physicians on which subset of patients may benefit from the addition of ICS¹

(BUSINESS WIRE)-- Boehringer Ingelheim welcomes the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy which now positions a combination of a LAMA (long-acting anticholinergic) and a LABA (long-acting beta2-agonist), as a mainstay treatment for people with Chronic Obstructive Pulmonary Disease (COPD) in GOLD groups B-D. ...

Source : http://me-newswire.net//news/19077/en...